Vibha Lama is a Respiratory physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1500 East Medical Center Dr
3rd Floor Taubman Ctr Recp C
Ann Arbor, MI 481095360
Telephone
734-647-9342Provider last certified this registry record 19 Jun 2023.
Clinical trials
- Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)
Sponsor: University of Michigan
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Mallinckrodt Hospital Products Inc.Program year20247 payments$19,656openpaymentsdata.cms.gov ↗
- JAZZ PHARMACEUTICALS INC.Program year20231 payment
- Mallinckrodt Hospital Products Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
31%Macrolide Antimicrobial15.3%Azithromycin100%Part D≥15 patientsShort-acting sulfonamides8.5%Sulfamethoxazole-Trimethoprim100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
26.9%Corticosteroid21.8%Prednisone100%Part D≥13 patientsProton pump inhibitor5.1%Omeprazole100%Part D<11 patientsDermatology
14.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor14.3%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
4 NIH research awards on record, funded 2004–2023 per NIH RePORTER. The latest:
- Pathogenesis of Restrictive Allograft Syndrome Post-Lung Transplantation
University of Michigan at Ann Arbor
FY2023$671,112R01HL162171 - Translational Dysregulation Driving Mesenchymal Cell Fibrogenic Transformation and Chronic Lung Allograft Dysfunction
University of Michigan at Ann Arbor
FY2023$1R01HL094622 - Pathogenesis of Restrictive Allograft Syndrome Post-Lung Transplantation
University of Michigan at Ann Arbor
FY2022$701,112R01HL162171
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”